New Drug Approvals in China: An International Comparative Analysis, 2019-2023
Despite COVID-19 challenges, China has improved in both the quantity and speed of new drug approvals, narrowing timeline gaps with major markets and enhancing its global pharmaceutical presence.
Authors
- Yilong Yan (ORCID: https://orcid.org/0009-0002-4454-386X)
- Weilin Shi
- Min Long
- Xiaolin Yue (ORCID: https://orcid.org/0000-0002-8351-9187)
- Ziming Li (ORCID: https://orcid.org/0009-0005-5718-2145)
- Xiangyu Guo (ORCID: https://orcid.org/0000-0001-7099-6606)
- Zhigang Zhao (ORCID: https://orcid.org/0000-0002-4484-0453)
- Fanpu Kong
Institutions
- Capital Medical University (CN)
- Beijing Tian Tan Hospital (CN)
- Beijing Institute of Big Data Research (CN)
- Tsinghua University (CN)
Publication Details
- Journal
- Drug Design Development and Therapy
- Published
- 2025-04-01
- DOI
- https://doi.org/10.2147/dddt.s514132
- Citations
- 2
- Primary Topic
- Pharmaceutical Economics and Policy
- Type
- article
- Field-Weighted Citation Impact
- 6.26